Biomarin Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.02.16	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q4 Earnings Report (RTTNews)
20.01.16	Sarepta's DMD Drug - Thumbs Up Or Thumbs Down? (RTTNews)
15.01.16	ADMP On Watch, It's A Thumbs Down For BMRN, No Pain, All Gain For IPCI (RTTNews)
14.01.16	BioMarin Gets Complete Response Letter From FDA For Kyndrisa - Quick Facts (RTTNews)
12.01.16	ONCE Braces For Busy Year, ELOS Rises After Hours, GWPH Under Scanner (RTTNews)
25.11.15	FDA Panel Pours Cold Water On Biomarin's Muscular Dystrophy Treatment (RTTNews)
25.11.15	All Well Says ADRO As Stock Slips, LLY Gets FDA Nod, BMRN, OCUL On Watch (RTTNews)
23.11.15	NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England (GlobeNewswire)
29.10.15	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q3 Earnings Report (RTTNews)
01.10.15	BioMarin Acquires All Global Rights To Kuvan And Pegvaliase From Merck Serono (RTTNews)
30.09.15	Sarepta To Appeal USPTO Decision In Patent Interference Case With BioMarin (RTTNews)
29.09.15	ZSAN Abuzz With Activity, Titan Gets FDA Date, ESPR Down After Hours (RTTNews)
21.09.15	BMRN Settles Lawsuit With Dr Reddy's, HRTX Gets FDA Date, TCON On Track (RTTNews)
18.09.15	BioMarin Announces Kuvan Patent Challenge Settlement (RTTNews)
24.08.15	Medivation To Acquire Worldwide Rights To Talazoparib From BioMarin (RTTNews)
20.08.15	MCUR's VLU Trial Is Futile, CRBP, CEMP On Fast Track, INO Takes A Shot At MERS (RTTNews)
19.08.15	FDA Grants Rare Pediatric Disease Designation For Drisapersen To Treat DMT (RTTNews)
03.08.15	BioMarin Pharma Q2 Loss Widens; 2015 Guidance Unchanged - Quick Facts (RTTNews)
03.08.15	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
21.07.15	BMRN Expands Breast Cancer Trial, EXEL's Meteor Shines, HZNP Widens Horizons (RTTNews)
18.06.15	EW Gets FDA Nod, BMRN's Achondroplasia Trial Promising, Watch Out For POZN (RTTNews)
18.06.15	BioMarin Surges On Positive Results From Phase-2 Study Of Dwarfism Drug (RTTNews)
08.06.15	BioMarin Submits Drisapersen MAA To EMA To Treat DMD Amenable To Exon51 Skipping (RTTNews)
20.05.15	Sarepata Soars As Investors Cheer DMD Drug's Progress (RTTNews)
30.04.15	BioMarin Q1 Loss Widens - Quick Facts (RTTNews)
28.04.15	CRY Has A Reason To Smile, MDXG Lifts Outlook, MYL Rejects Teva Bid (RTTNews)
06.03.15	GALE On The Radar, CALA Surges After-Hours, Capricor Uplisted, CPRX On A High (RTTNews)
26.02.15	AMGN Study Meets Goal, BRLI Hits New High, DPRX On Watch, GMED Opens Wallet (RTTNews)
25.02.15	BioMarin Loss Narrower Than Estimates (RTTNews)
22.01.15	BioMarin Prices Offering Of 8.5 Mln Shares At $93.25 Per Share (RTTNews)
29.12.14	BioMarin Pharma Reports Approval Of VIMIZIM In Japan For Morquio A Syndrome (RTTNews)
24.12.14	BioMarin: Expiration Of Waiting Period Under HSR Act For Prosena Acquisition (RTTNews)
10.12.14	BioMarin Pharma Says FDA Grants Orphan Drug Designation For BMN 250 (RTTNews)
10.12.14	BioMarin Pharma: VIMIZIM Approved In Brazil For Treatment Of Morquio A Syndrome (RTTNews)
24.11.14	BioMarin To Buy Prosensa For Up To $840 Mln - Update (RTTNews)
24.11.14	BioMarin Pharma Offers To Buy Prosensa For $17.75 Per Share - Quick Facts (RTTNews)
24.10.14	BioMarin Pharma Swings To Profit, Revenue Misses Estimate; Lift FY Guidance (RTTNews)
30.07.14	BioMarin Pharma Q2 Loss Widens - Quick Facts (RTTNews)
07.07.14	BioMarin's Vimizim Approved In Canada For Treatment Of Morquio A Syndrome (RTTNews)
02.05.14	BioMarin Pharma Q1 Loss Narrows - Quick Facts (RTTNews)
29.04.14	FURX To Be Snapped Up, NVIV Initiates First Clinical Trial, NVAX Up After-hours (RTTNews)
28.04.14	BioMarin: European Commission Okays Vimizim To Treat Morquio A Syndrome (RTTNews)
14.04.14	BioMarin Pharma Says FDA Extends Market Exclusivity Six Months For Kuvan Powder (RTTNews)
05.03.14	BioMarin Expects Proceeds Of $119 Mln. From 1.5 Mln. Share Offer (RTTNews)
21.02.14	BMRN Awaits EMA Nod, KIN Hits A High, Nuvilex Gets Rich, OHRP A Sight Better (RTTNews)
18.02.14	BioMarin Pharma Expects FY13 Loss Of $185 - $160 Mln (RTTNews)
14.02.14	BioMarin Pharma Gets FDA Approval For VIMIZIM - Quick Facts (RTTNews)
14.01.14	BioMarin: First Patient Dosed In Phase 2 Trial Of BMN 111 In Achondroplasia (RTTNews)
08.01.14	Catalyst Pharma Meets Primary Endpoint For Cardiac Safety In Firdapse Evaluation (RTTNews)
04.12.13	BioMarin Pharma Submits NDS For Vimizim Under Priority Review Status (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	534.00	0.56 %	K V
Roche Hldg G	252.40	0.40 %	K V
Nestle	76.08	0.32 %	K V
Givaudan	3’883.00	0.00 %	K V
Sonova Hldg	304.60	0.00 %	K V
CieFinRichemont	121.50	-0.69 %	K V
Holcim	87.74	-0.77 %	K V
Sika	226.70	-0.83 %	K V
ABB	48.94	-1.21 %	K V
Logitech Intl	70.50	-2.06 %	K V

mehr

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

16.09.24

NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus

16.09.24

NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag

16.09.24

Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer

16.09.24

Verluste in New York: NASDAQ Composite verliert zum Start

06.08.24

Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus

06.08.24

Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich